A consortium led by Amniotics has been funded by EU with €3.8 Million over three years for the development of iPS derived enhanced Natural Killer (NK) cells. The other consortium participants are Lund University, Medizinische Hochschule Hannover, and University of Copenhagen.

The goal of the HyperTargIPS-NK project is to combine novel technologies from the three research laboratories with Amniotics expertise to develop a revolutionary therapeutic modality for patients with cancer. The proposed treatment is based on laboratory generated natural killer (NK) cells, genetically modified to a hyperactive state to ensure elimination of the tumor cells.

-It is a great honor for Amniotics to be a part of this consortium which aims to bring transformative therapies to cancer patients. Amniotics has a patent portfolio within the area of blood cell production and NK cells, thus our participation in this EU project is of particular value to the company’s future cell therapy development, says Jan Talts, COO of Amniotics and the project coordinator.

Funded by EU

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council (EIC). Neither the European Union nor the granting authority can be held responsible for them.

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.